Found 11 results for raj-vuppalanchi-md
A listing of raj-vuppalanchi-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Liver Research Study for Heavy Drinkers
R
Raj Vuppalanchi, MD
Do you have liver damage because of excessive alcohol use? Join our study!Researchers at the Indiana University School of Medicine are looking for adult volunteers to take part in a study looking at the link between heavy drinking and liver disease.Your participation may help researchers to gain knowledge that may …
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrohosis Due to Nash/Mash
R
Raj Vuppalanchi, MD
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.THIS STUDY IS ENROLLING BY INVITATION ONLY
Integrated Therapies for Alcohol Use in Alcohol-Associated Liver Disease
R
Raj Vuppalanchi, MD
To determine whether interventions directed to treat AUD integrated with sAH therapies will improve a composite endpoint of alcohol and liver-related events at 6 months compared to usual care for AUD (primary endpoint)To compare 90-day survival in patients receiving F-652 with those receiving up to 28 days of prednisone using …
A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium on Normalization of Alkaline Phosphatase Levels in Patients with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
R
Raj Vuppalanchi, MD
This is a Double-blind, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy of Saroglitazar Magnesium 1 mg on normalization of ALP in patients having ALP > ULN to THIS STUDY IS ENROLLING BY INVITATION ONLY
A phase 1, open-label, single arm study to evaluate pharmacokinetics, safety, and tolerability of Saroglitazar Magnesium dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease
R
Raj Vuppalanchi, MD
To evaluate PK after Saroglitazar Magnesium 1 mg dose on alternate days in subjects with moderate hepatic impairment with cirrhosis due to CLD based on Child-Pugh-Turcotte (CPT) score.To assess safety and tolerability of Sa-roglitazar Magnesium 1 mg dose on alter-nate days in subjects with moderate hepatic impairment with cirrhosis due …
A Phase 3B/4, Multicenter, Parallel-Group, Double-Blind, Placebo Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants With Primary Biliary Cholangitis (Pbc)
R
Raj Vuppalanchi, MD
The purpose of this study is to evaluate the effect of saroglitazar magnesium compared to placebo, based on time to the first occurrence of the defined clinical outcome events in participants with PBC.THIS STUDY IS ENROLLING BY INVITATION ONLY
Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in High-Risk Patients Presenting to Primary Care
R
Raj Vuppalanchi, MD
This study will provide the first comprehensive real-world prevalence data on MASLD in a primary care-based high-risk population, using validated non-invasive imaging. Results will inform evidence-based screening guidelines, support integration of FibroScan into PCP workflows, and facilitate early intervention to reduce progression to advanced liver disease. Identified predictors of significant …
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis
R
Raj Vuppalanchi, MD
Why is this study being done?In some people, the liver makes an abnormal version of the alpha-1 antitrypsin (AAT) protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver …
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (Synergy-Outcomes)
R
Raj Vuppalanchi, MD
This multicenter, randomized, parallel-arm, double-blind, placebo-controlled Phase 3 umbrella- type master protocol aims to create a framework for simultaneously evaluating the safety and efficacy of multiple pharmacologic agents (interventions) for the treatment of high-risk metabolic dysfunction-associated steatotic liver disease.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study team will …
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (Mash) (Zenith-1)
R
Raj Vuppalanchi, MD
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.THIS STUDY IS ENROLLING BY INVITATION ONLY
1 - 10 of 11
- 1
- 2
Please choose between Voice or SMS based delivery of verification code
or